From Podium To Practice
Drs. Wassim Mchayleh and Neil Iyengar review the rapidly evolving role of antibody drug conjugates in first-line metastatic triple-negative breast cancer. They compare key data from ASCENT-03, ASCENT-04, and TROPION-Breast02, including how disease-free interval, prior pembrolizumab exposure, PD-L1 status, crossover, and overall survival interpretation influence treatment selection. The conversation also highlights practical differences between sacituzumab govitecan and datopotamab deruxtecan, including schedule, neutropenia, diarrhea, mucositis, ocular toxicity, ILD risk, and the need for proactive supportive care. Overall, they emphasize that having multiple ADC options marks a major shift in TNBC care and requires shared decision-making based on disease burden, toxicity profile, and patient priorities.
Contributors:
Dr. Wassim Mchayleh is Medical Director of Breast Oncology at Advent Health.
Dr. Neil Iyengar is Co-Director of Breast Oncology at Emory University School of Medicine.